Editorial: Case reports in hematological malignancies: 2022.
作者信息
Antar Ahmad, Szallasi Arpad, Imataki Osamu
机构信息
Department of Hematology-Oncology, Almoosa Specialist Hospital, Al-Ahsa, Saudi Arabia.
Faculty of Medicine, Semmelweis University, Budapest, Hungary.
出版信息
Front Oncol. 2023 Aug 21;13:1272547. doi: 10.3389/fonc.2023.1272547. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Case reports in hematological malignancies: 2022.
Front Oncol. 2023 Aug 21;13:1272547. doi: 10.3389/fonc.2023.1272547. eCollection 2023.
2
Adoptive immunotherapy for hematological malignancies: Current status and new insights in chimeric antigen receptor T cells.
Blood Cells Mol Dis. 2016 Nov;62:49-63. doi: 10.1016/j.bcmd.2016.11.001. Epub 2016 Nov 10.
3
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
4
Myelodysplastic syndrome following chimeric antigen receptor T-cell therapy treated with allogenic stem cell transplantation.
Immunotherapy. 2023 Apr;15(6):401-407. doi: 10.2217/imt-2022-0205. Epub 2023 Mar 23.
5
CAR T-Cell Therapy in Hematological Malignancies.
Int J Mol Sci. 2021 Aug 20;22(16):8996. doi: 10.3390/ijms22168996.
6
Progress on CAR-T cell therapy for hematological malignancies.
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2022 Apr 25;51(2):192-203. doi: 10.3724/zdxbyxb-2022-0055.
7
Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data.
Pharmaceutics. 2020 Feb 24;12(2):194. doi: 10.3390/pharmaceutics12020194.
8
Nutritional status alterations after chimeric antigen receptor T cell therapy in patients with hematological malignancies: a retrospective study.
Support Care Cancer. 2022 Apr;30(4):3321-3327. doi: 10.1007/s00520-021-06639-2. Epub 2022 Jan 5.
9
Enrollment of Black Participants in Pivotal Clinical Trials Supporting US Food and Drug Administration Approval of Chimeric Antigen Receptor-T Cell Therapy for Hematological Malignant Neoplasms.
JAMA Netw Open. 2022 Apr 1;5(4):e228161. doi: 10.1001/jamanetworkopen.2022.8161.
10
Secondary myeloid neoplasms after CD19 CAR T therapy in patients with refractory/relapsed B-cell lymphoma: Case series and review of literature.
Front Immunol. 2023 Jan 13;13:1063986. doi: 10.3389/fimmu.2022.1063986. eCollection 2022.
本文引用的文献
1
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.
Leukemia. 2022 Jul;36(7):1703-1719. doi: 10.1038/s41375-022-01613-1. Epub 2022 Jun 22.
2
TEMPI syndrome associated with IgM monoclonal gammopathy.
Blood. 2022 Feb 24;139(8):1254. doi: 10.1182/blood.2021014393.
3
Preemptive Interferon-α Therapy Could Protect Against Relapse and Improve Survival of Acute Myeloid Leukemia Patients After Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Results of Two Registry Studies.
Front Immunol. 2022 Jan 28;13:757002. doi: 10.3389/fimmu.2022.757002. eCollection 2022.
4
Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management.
Am J Hematol. 2022 Apr;97(4):491-505. doi: 10.1002/ajh.26481. Epub 2022 Feb 9.
5
Neurologic Complications of Cancer Therapies.
Curr Neurol Neurosci Rep. 2021 Nov 24;21(12):66. doi: 10.1007/s11910-021-01151-w.
6
A viral cause of APL.
Blood. 2021 Nov 4;138(18):1653-1655. doi: 10.1182/blood.2021013630.
7
Torque teno mini virus as a cause of childhood acute promyelocytic leukemia lacking PML/RARA fusion.
Blood. 2021 Nov 4;138(18):1773-1777. doi: 10.1182/blood.2021011677.
8
Effective use of monoclonal antibodies for treatment of persistent COVID-19 infection in a patient on rituximab.
BMJ Case Rep. 2021 Aug 3;14(8):e243469. doi: 10.1136/bcr-2021-243469.
9
Current views on the genetic landscape and management of variant acute promyelocytic leukemia.
Biomark Res. 2021 May 6;9(1):33. doi: 10.1186/s40364-021-00284-x.
10
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer's dementia.
Alzheimers Res Ther. 2021 Mar 17;13(1):62. doi: 10.1186/s13195-021-00795-7.
Zotero 插件